The goal of the current study was to investigate the role of CHRNA4 and CHRNB2 in lifetime DSM-IV ND symptom counts in two large young adult samples ascertained through clinical referrals for drug treatment. These samples are unique because subjects were recruited as young adults and have been assessed longitudinally. SNPs in each gene were selected to capture most common genetic variation and family-based association tests (FBAT) were employed to test for association with DSM-IV ND symptoms.
